Biotech Values

[randychub]

vrtx - from a poster on the yahoo board. To me safety is the issue that with 8 patients taking the drug is still up in the air.

"windwalker"

To me, that makes no sense at all. Firstly, far as I could tell, the "potential" of VX950 is based on the same amount of data as BILN had (with about the same level of effectiveness) before - well, you know what happened. Secondly, why wouldn't VRTX set the study up to maximize their chance of success? i.e., plan for the full 48 weeks and - if the 3-month data are compelling - GREAT - off to the races! But that isn't what they're doing is it? No, no, no...for some hitherto unkown reason, VRTX does not want to go past 3 months. "WHY," I must ask myself - why, why why? Can't make enough pills? Inadequate exposure safety margin? Can't afford the pegIFN? Why, why, why?